(NASDAQ: CUE) Cue Biopharma's forecast annual revenue growth rate of 36.9% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.19%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.95%.
Cue Biopharma's revenue in 2024 is $7,020,000.On average, 4 Wall Street analysts forecast CUE's revenue for 2024 to be $471,451,019, with the lowest CUE revenue forecast at $194,573,264, and the highest CUE revenue forecast at $841,529,367. On average, 4 Wall Street analysts forecast CUE's revenue for 2025 to be $668,845,595, with the lowest CUE revenue forecast at $97,286,632, and the highest CUE revenue forecast at $2,188,949,220.
In 2026, CUE is forecast to generate $878,790,147 in revenue, with the lowest revenue forecast at $194,573,264 and the highest revenue forecast at $1,702,516,060.